Biotech Values

[caravon]

Speaking about CLVS:

- Their game plan is
-- To accelerate their clinical CO-1686 trials in 2015 (including in 1-line NSCLC and in combo with other drugs)
-- To get an Asian partner as late as possible to have a better deal. CLVS expects that the Asian market will be twice as large as US+EU markets.
-- Conduct clinical trials for two other cancer drugs with approvals in ~2017

Consequently, CLVS will need money to pay for these clinical trials by themselves.

Astra-Z will present their AZD 9291 results in 2-line NSCLC at ESMO later this month. CLVS will present their data in Barcelona in late Nov. 2014 So, CLVS decided to play safe and raise money now.

As for ENTA getting royalties from ABBV for HCV or be a 50/50 partner, I wish them to go for 50/50. I want to get my ENTA money ASAP. ABBV will not allow ENTA a partnership deal. It will be just crazy.